Business
Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
Safety and Pharmacokinetic Data Support Dosing ofART26.12 in Fed or Fasted Conditions Completion of Positive Single Ascending Dose Study with a Preliminary Food Effect Assessment Advances ART26.12 Toward Multiple Ascending Dose Trial SOLANA BEACH, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neuro
About this update from Artelo Biosciences, Inc.
[{"type":"image","alt":"Artelo Biosciences","displaySize":"","headline":null,"caption":"Artelo Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":183,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/0fcfe43e16f7cfc8e2a0ef70f1c6364e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dtRWcM_YXYcz7bexobLzxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0fcfe43e16f7cfc8e2a0ef70f1c6364e","width":183,"height":80}},"lazy":false},{"type":"text","content":"Safety and Pharmacokinetic Data Support Dosing ofART26.12 in Fed or Fasted Conditions","length":86,"tagName":"p"},{"type":"text","content":"Completion of Positive Single Ascending Dose Study with a Preliminary Food Effect Assessment Advances ART26.12 Toward Multiple Ascending Dose Trial ","length":148,"tagName":"p"},{"type":"text","content":"SOLANA BEACH, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced encouraging results from its preliminary food effect evaluation with ART26.12. This assessment was conducted as a part of the successful single ascending dose (SAD) Phase 1 clinical trial evaluating ART26.12, the first selective oral small molecule fatty acid binding protein 5 (FABP5) inhibitor dosed in the clinic.","length":624,"tagName":"p"},{"type":"text","content":"The food effect interrogation was designed to assess the pharmacokinetics and safety profile ART26.12 in healthy volunteers under both fed and fasted conditions. The selected dose was based on previously established safety and pharmacokinetic data from the SAD study, where there were no drug-related adverse events reported.","length":325,"tagName":"p"},{"type":"text","content":"Key findings include:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Favorable Safety Profile: Participants received three single doses of ART26.12 separated by 7-day intervals. No serious adverse events, safety concerns, or tolerability issues were identified. All reported adverse events were mild, self-limiting, and consistent with those observed in the SAD study.","length":299,"tagName":"p"}]},...